David Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Wang has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Albert Lai
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles , Los Angeles, CA
31 shared publications - Alvaro G. Alvarado
Department of Psychiatry and Behavioral Sciences and the UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, California
31 shared publications - Amy Pham
Department of Psychiatry and Behavioral Sciences and the UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, California
31 shared publications - Fuying Gao
Department of Psychiatry and Behavioral Sciences and the UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, California
31 shared publications - Haocheng Qi
Department of Psychiatry and Behavioral Sciences and the UCLA Intellectual and Developmental Disabilities Research Center, David Geffen School of Medicine, UCLA, Los Angeles, California
31 shared publications - Harley I. Kornblum
Department of Psychiatry and Human Behavior, University of California, Los Angeles , Los Angeles, CA 90095
31 shared publications
Latest Publications
- 29 July 2026
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 284 (4) , 689-698
Burn Injury Rewires Immune and Neuronal Extracellular Vesicle Communication
Objective: We examined extracellular vesicle (EV) protein alterations after burn injury to elucidate molecular pathways linking immune–neural communication and the pathophysiology of burns. Background: Severe burn injury triggers widespread inflammation and metabolic stress with downstream consequences. EVs are essential mediators of cell-to-cell communication and protein transport for regulating inflammation, metabolism, and neuronal signaling that may reflect burn-related alterations. Methods: Plasma EVs from 37 adult burn patients (≥15% total body surface area burn [TBSA]) and 21 nonburn controls were analyzed. An age-restricted subcohort (P -value<0.05) distinguishing burns from controls were CRP, ITGA11, MYH9, CALR, and ANTXR2. GO ORA, Reactome GSEA, and IPA consistently identified enrichment of immune activation and inflammatory regulation pathways, including immune cell chemotaxis, acute-phase signaling, cytokine signaling, complement activation, coagulation, and cellular stress pathways. Similar inflammatory pathway enrichment persisted in the age-restricted subcohort. Exploratory analyses of cell type-enriched EVs demonstrated distinct proteomic trends across immune and neuronal EV populations, although no subtype-specific proteins exhibited statistical significance. Conclusions: Burn injury profoundly alters EV cargo across general, immune, and neuronal types, reflecting proinflammatory and neuroimmune-associated signaling. This coordinated EV remodeling may reflect the hyperinflammatory responses, altered healing, and downstream biological pathway alterations. EV-based biomarkers may enable improved diagnostic and therapeutic strategies to mitigate dysregulated immune and healing responses in burn patients.
- 29 July 2026
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 284 (4) , 689-698
Burn Injury Rewires Immune and Neuronal Extracellular Vesicle Communication
Objective: We examined extracellular vesicle (EV) protein alterations after burn injury to elucidate molecular pathways linking immune–neural communication and the pathophysiology of burns. Background: Severe burn injury triggers widespread inflammation and metabolic stress with downstream consequences. EVs are essential mediators of cell-to-cell communication and protein transport for regulating inflammation, metabolism, and neuronal signaling that may reflect burn-related alterations. Methods: Plasma EVs from 37 adult burn patients (≥15% total body surface area burn [TBSA]) and 21 nonburn controls were analyzed. An age-restricted subcohort (P -value<0.05) distinguishing burns from controls were CRP, ITGA11, MYH9, CALR, and ANTXR2. GO ORA, Reactome GSEA, and IPA consistently identified enrichment of immune activation and inflammatory regulation pathways, including immune cell chemotaxis, acute-phase signaling, cytokine signaling, complement activation, coagulation, and cellular stress pathways. Similar inflammatory pathway enrichment persisted in the age-restricted subcohort. Exploratory analyses of cell type-enriched EVs demonstrated distinct proteomic trends across immune and neuronal EV populations, although no subtype-specific proteins exhibited statistical significance. Conclusions: Burn injury profoundly alters EV cargo across general, immune, and neuronal types, reflecting proinflammatory and neuroimmune-associated signaling. This coordinated EV remodeling may reflect the hyperinflammatory responses, altered healing, and downstream biological pathway alterations. EV-based biomarkers may enable improved diagnostic and therapeutic strategies to mitigate dysregulated immune and healing responses in burn patients.
- Open Access
- 5 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (9) , 7385-7400
Prototyping Minimal Extracellular Vesicle Mimetics Using Cell-Free Synthesis
The many surface proteins on extracellular vesicles (EVs) allow them to target recipient cells and modulate cellular responses. Despite their importance, relating surface protein and EV function is challenging due to surface protein heterogeneity. Here, we create a bottom-up, cell-free protein-synthesis platform to engineer artificial nanovesicles (ANVs) that display different EV surface protein domains. The platform is termed VESSEL (Vesicle Engineering Systems using Synthetic Expression and Loading). The surface proteins are selected based on proteomics data of native EVs from placental mesenchymal stem cells (PMSCs). To create VESSEL, we establish a protein anchor based on the bacteria membrane protein Aquaporin-Z. This anchor allows the flexible and cell-free protein synthesis of 39 different EV surface protein domains, each anchoring into more than 108 ANVs per μL. Furthermore, we measure the ANVs using high-fidelity assays, including single-ANV flow cytometry, super-resolution imaging, and vesicle-based ELISA. Next, we show the impact of each EV surface protein on cellular uptake. Specifically, we find that certain EV surface protein domains govern ANV uptake into HEK293FT cells, explaining the variable observations in the field. We discovered new proteins, such as CADM1 and NPTN, that mediate high-efficiency cellular uptake. Additionally, five proteins were selected for our neuroprotection assay, where three proteins were significant in increasing SH-SY5Y neurite growth. Our work demonstrates a high-throughput cell-free synthesis platform for studying surface proteins of EVs. It enables the systematic interrogation of EV's function as "signalosomes" and facilitates the designing of well-defined EV mimetics to mediate cellular function.
- 5 February 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (9) , 7385-7400
Open AccessPrototyping Minimal Extracellular Vesicle Mimetics Using Cell-Free Synthesis
The many surface proteins on extracellular vesicles (EVs) allow them to target recipient cells and modulate cellular responses. Despite their importance, relating surface protein and EV function is challenging due to surface protein heterogeneity. Here, we create a bottom-up, cell-free protein-synthesis platform to engineer artificial nanovesicles (ANVs) that display different EV surface protein domains. The platform is termed VESSEL (Vesicle Engineering Systems using Synthetic Expression and Loading). The surface proteins are selected based on proteomics data of native EVs from placental mesenchymal stem cells (PMSCs). To create VESSEL, we establish a protein anchor based on the bacteria membrane protein Aquaporin-Z. This anchor allows the flexible and cell-free protein synthesis of 39 different EV surface protein domains, each anchoring into more than 108 ANVs per μL. Furthermore, we measure the ANVs using high-fidelity assays, including single-ANV flow cytometry, super-resolution imaging, and vesicle-based ELISA. Next, we show the impact of each EV surface protein on cellular uptake. Specifically, we find that certain EV surface protein domains govern ANV uptake into HEK293FT cells, explaining the variable observations in the field. We discovered new proteins, such as CADM1 and NPTN, that mediate high-efficiency cellular uptake. Additionally, five proteins were selected for our neuroprotection assay, where three proteins were significant in increasing SH-SY5Y neurite growth. Our work demonstrates a high-throughput cell-free synthesis platform for studying surface proteins of EVs. It enables the systematic interrogation of EV's function as "signalosomes" and facilitates the designing of well-defined EV mimetics to mediate cellular function.
- Open Access
- 2 January 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (4) , 2252-2263
Hijacking exosome biogenesis: viral glycoproteins as modular scaffolds for engineering functionalized extracellular vesicles
Diverse viral glycoproteins (VSVG, HSV-gpB, SARS-CoV-1 spike) insert into EV membranes via endosomal trafficking, independent of viral assembly. Sorting depends on transmembrane/cytoplasmic domains. VSVG-EVs show >2× higher uptake.
- 2 January 2026
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 18 (4) , 2252-2263
Open AccessHijacking exosome biogenesis: viral glycoproteins as modular scaffolds for engineering functionalized extracellular vesicles
Diverse viral glycoproteins (VSVG, HSV-gpB, SARS-CoV-1 spike) insert into EV membranes via endosomal trafficking, independent of viral assembly. Sorting depends on transmembrane/cytoplasmic domains. VSVG-EVs show >2× higher uptake.
- Open Access
- 21 October 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (10) , e70175
Hybrid Extracellular Vesicles With Combined Functional Properties From Mesenchymal Stem Cells and Astrocytes for Targeted Neurodegenerative Disease Applications
Extracellular vesicles (EVs) have been investigated as nanotherapeutics and drug delivery systems for a wide range of disease indications. However, translational application of EVs is challenging due to their physical heterogeneity and variation in functional potency. The current study generated a novel hybrid EV formulation by membrane fusion of mesenchymal stem/stromal cell‐derived EVs with astrocyte‐derived EVs and defined its physicochemical and functional properties. Both EV populations have translational potential for neurodegenerative disease applications—a disease area with limited treatment strategies due to its complex disease biology requiring multi‐faceted therapeutic approaches. However, individual EV sources lack the full set of therapeutic properties needed for comprehensive treatment. Stem cell‐derived EVs possess general neuroprotective and anti‐inflammatory effects but lack widespread blood–brain barrier penetration and specific neurodegenerative pathology targeting. Astrocytes are uniquely involved in key neuronal processes but are prone to adopting neuroinflammatory phenotypes in disease states. Using super resolution microscopy and quantitative proteomic analysis, we characterized, optimized, and validated a hybrid EV formulation for its brain cell targeting, neuroprotective function, and immunomodulatory capability. These results establish a platform for EV engineering through EV‐EV hybridization and demonstrate the potential of one formulation for neurodegenerative applications.
- 21 October 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (10) , e70175
Open AccessHybrid Extracellular Vesicles With Combined Functional Properties From Mesenchymal Stem Cells and Astrocytes for Targeted Neurodegenerative Disease Applications
Extracellular vesicles (EVs) have been investigated as nanotherapeutics and drug delivery systems for a wide range of disease indications. However, translational application of EVs is challenging due to their physical heterogeneity and variation in functional potency. The current study generated a novel hybrid EV formulation by membrane fusion of mesenchymal stem/stromal cell‐derived EVs with astrocyte‐derived EVs and defined its physicochemical and functional properties. Both EV populations have translational potential for neurodegenerative disease applications—a disease area with limited treatment strategies due to its complex disease biology requiring multi‐faceted therapeutic approaches. However, individual EV sources lack the full set of therapeutic properties needed for comprehensive treatment. Stem cell‐derived EVs possess general neuroprotective and anti‐inflammatory effects but lack widespread blood–brain barrier penetration and specific neurodegenerative pathology targeting. Astrocytes are uniquely involved in key neuronal processes but are prone to adopting neuroinflammatory phenotypes in disease states. Using super resolution microscopy and quantitative proteomic analysis, we characterized, optimized, and validated a hybrid EV formulation for its brain cell targeting, neuroprotective function, and immunomodulatory capability. These results establish a platform for EV engineering through EV‐EV hybridization and demonstrate the potential of one formulation for neurodegenerative applications.
- Open Access
- 24 October 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (44) , 30293-30306
Widespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles
In utero gene editing with mRNA-based therapeutics has the potential to revolutionize the treatment of neurodevelopmental disorders. However, a critical bottleneck in clinical application has been the lack of mRNA delivery vehicles that can efficiently transfect cells in the brain. In this report, we demonstrate that in utero intracerebroventricular (ICV) injection of densely PEGylated lipid nanoparticles (ADP-LNPs) containing an acid-degradable PEG-lipid can safely and effectively deliver mRNA for gene editing enzymes to the fetal mouse brain, resulting in successful transfection and editing of brain cells. ADP-LNPs containing Cre mRNA transfected 30% of the fetal brain cells in Ai9 mice and had no detectable adverse effects on fetal development and postnatal growth. In addition, ADP-LNPs efficiently transfected neural stem and progenitor cells in Ai9 mice with Cre mRNA, which subsequently proliferated and caused over 40% of the cortical neurons and 60% of the hippocampal neurons to be edited in treated mice 10 weeks after birth. Furthermore, using Angelman syndrome, a paradigmatic neurodevelopmental disorder, as a disease model, we demonstrate that ADP-LNPs carrying Cas9 mRNA and gRNA induced indels in 21% of brain cells within 7 days postpartum, underscoring the precision and potential of this approach. These findings demonstrate that LNP/mRNA complexes have the potential to be a transformative tool for in utero treatment of neurodevelopmental disorders and set the stage for a frontier in treating neurodevelopmental disorders that focuses on curing genetic diseases before birth.
- 24 October 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (44) , 30293-30306
Open AccessWidespread Gene Editing in the Brain via In Utero Delivery of mRNA Using Acid-Degradable Lipid Nanoparticles
In utero gene editing with mRNA-based therapeutics has the potential to revolutionize the treatment of neurodevelopmental disorders. However, a critical bottleneck in clinical application has been the lack of mRNA delivery vehicles that can efficiently transfect cells in the brain. In this report, we demonstrate that in utero intracerebroventricular (ICV) injection of densely PEGylated lipid nanoparticles (ADP-LNPs) containing an acid-degradable PEG-lipid can safely and effectively deliver mRNA for gene editing enzymes to the fetal mouse brain, resulting in successful transfection and editing of brain cells. ADP-LNPs containing Cre mRNA transfected 30% of the fetal brain cells in Ai9 mice and had no detectable adverse effects on fetal development and postnatal growth. In addition, ADP-LNPs efficiently transfected neural stem and progenitor cells in Ai9 mice with Cre mRNA, which subsequently proliferated and caused over 40% of the cortical neurons and 60% of the hippocampal neurons to be edited in treated mice 10 weeks after birth. Furthermore, using Angelman syndrome, a paradigmatic neurodevelopmental disorder, as a disease model, we demonstrate that ADP-LNPs carrying Cas9 mRNA and gRNA induced indels in 21% of brain cells within 7 days postpartum, underscoring the precision and potential of this approach. These findings demonstrate that LNP/mRNA complexes have the potential to be a transformative tool for in utero treatment of neurodevelopmental disorders and set the stage for a frontier in treating neurodevelopmental disorders that focuses on curing genetic diseases before birth.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Figure S5. ASPN expression is enriched in IDH mutant LGG and regulated by D-2HG
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Figure S5. ASPN expression is enriched in IDH mutant LGG and regulated by D-2HG
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Data from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
A key feature distinguishing high-grade glioma (HG) from low-grade glioma (LG) is the extensive neovascularization and endothelial hyperproliferation. Prior work has shown that tumor-associated vasculature from HG is molecularly and functionally distinct from normal brain vasculature and expresses higher levels of protumorigenic factors that promote glioma growth and progression. However, it remains unclear whether vessels from LG also express protumorigenic factors, and to what extent they functionally contribute to glioma growth. Here, we profile the transcriptomes of glioma-associated vascular cells (GVC) from IDH-mutant (mIDH) LG and IDH-wild-type (wIDH) HG and show that they exhibit significant molecular and functional differences. LG-GVC show enrichment of extracellular matrix–related gene sets and sensitivity to antiangiogenic drugs, whereas HG-GVC display an increase in immune response–related gene sets and antiangiogenic resistance. Strikingly, conditioned media from LG-GVC inhibits the growth of wIDH glioblastoma cells, whereas HG-GVC promotes growth. In vivo cotransplantation of LG-GVC with tumor cells reduces growth, whereas HG-GVC enhances tumor growth in orthotopic xenografts. We identify ASPORIN (ASPN), a small leucine-rich repeat proteoglycan, highly enriched in LG-GVC as a growth suppressor of wIDH glioblastoma cells in vitro and in vivo. Together, these findings indicate that GVC from LG and HG are molecularly and functionally distinct and differentially regulate tumor growth.Implications: This study demonstrated that vascular cells from IDH-mutant LG and IDH-wild-type HG exhibit distinct molecular signatures and have differential effects on tumor growth via regulation of ASPN-TGFβ1-GPM6A signaling.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
A key feature distinguishing high-grade glioma (HG) from low-grade glioma (LG) is the extensive neovascularization and endothelial hyperproliferation. Prior work has shown that tumor-associated vasculature from HG is molecularly and functionally distinct from normal brain vasculature and expresses higher levels of protumorigenic factors that promote glioma growth and progression. However, it remains unclear whether vessels from LG also express protumorigenic factors, and to what extent they functionally contribute to glioma growth. Here, we profile the transcriptomes of glioma-associated vascular cells (GVC) from IDH-mutant (mIDH) LG and IDH-wild-type (wIDH) HG and show that they exhibit significant molecular and functional differences. LG-GVC show enrichment of extracellular matrix–related gene sets and sensitivity to antiangiogenic drugs, whereas HG-GVC display an increase in immune response–related gene sets and antiangiogenic resistance. Strikingly, conditioned media from LG-GVC inhibits the growth of wIDH glioblastoma cells, whereas HG-GVC promotes growth. In vivo cotransplantation of LG-GVC with tumor cells reduces growth, whereas HG-GVC enhances tumor growth in orthotopic xenografts. We identify ASPORIN (ASPN), a small leucine-rich repeat proteoglycan, highly enriched in LG-GVC as a growth suppressor of wIDH glioblastoma cells in vitro and in vivo. Together, these findings indicate that GVC from LG and HG are molecularly and functionally distinct and differentially regulate tumor growth.Implications: This study demonstrated that vascular cells from IDH-mutant LG and IDH-wild-type HG exhibit distinct molecular signatures and have differential effects on tumor growth via regulation of ASPN-TGFβ1-GPM6A signaling.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Figure S2. Molecular and functional differences between LG- and HG-GVC
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Figure S2. Molecular and functional differences between LG- and HG-GVC
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth
Supplementary Table S6 from Low- and High-Grade Glioma-Associated Vascular Cells Differentially Regulate Tumor Growth